EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, CRSP: Crispr Therapeutics Ag

30 Dec 25 15:59
LAST:

53.19

CHANGE:
 0.78		OPEN:
54.30		HIGH:
54.39		ASK:
20.25		VOLUME:
791.2K
CHG(%):
1.45		PREV:
53.97		LOW:
52.98		BID:
17.88		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
30 Dec 2554.0654.1252.9853.191.36M
29 Dec 2554.5855.4153.8053.971.28M
26 Dec 2556.4856.5453.7655.081.41M
24 Dec 2556.4556.8355.2156.71652.9K
23 Dec 2557.1057.2455.8156.461.34M
22 Dec 2556.5059.1854.5057.901.19M
19 Dec 2555.3556.6855.0055.863.28M
18 Dec 2554.9057.0354.7754.841.34M
17 Dec 2555.7458.0054.6054.741.18M
16 Dec 2555.6857.5855.2955.971.14M

PROFILE

Name:Crispr Therapeutics Ag
About:CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Sector:Healthcare
Industry:Biotechnology
Address:Baarerstrasse 14, Zug, Switzerland, 6300
Website:https://www.crisprtx.com
CUSIP:H17182108
CIK:0001674416
ISIN:CH0334081137
FIGI:BBG00DBBGRX1
LEI:506700O6IRRIQLT3W370

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-14.28 
Forward P/E:-12.70 
PEG Ratio:-0.23 
Price to Sales:152.95 
Price to Book:3.30 
Profit Margin:-2.15 
Operating Margin:-149.18 
Return on Assets:-0.13 
Return on Equity:-0.25 
EPS Ratio:-5.40 
Revenue:38.05M 
Shares:90.95M 
Market Cap:4.838B 

TECHNICAL INDICATORS

MA5:55.083.6%
MA10:55.474.3%
MA20:56.025.3%
MA50:57.227.6%
MA100:58.8610.7%
MA200:51.463.4%
RSI14:34.93 
WPR14:-100.00 
MTM14:-4.40
ROC14:-0.08 
ATR:2.59 
Week High:57.247.6%
Week Low:52.980.4%
Month High:59.7712.4%
Month Low:51.003.4%
Year High:78.4847.5%
Year Low:30.0477.1%
Volatility:38.12 

RECENT SPLITS

Date Ratio
19 Jul 2016333333-100000